Novartis International AG Novartis investigational BYL719 alpelisib plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HRHER2 advanced breast cancer compared to fulvestrant alone

Novartis International AG: Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone

Novartis International AG / Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulve...

More From BioPortfolio on "Novartis International AG: Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone"